Compounds > n-(2-acetamido)iminodiacetic acid
Page last updated: 2024-12-07
n-(2-acetamido)iminodiacetic acid
Description
N-(2-acetamido)iminodiacetic acid (ADA) is a chelating agent with a high affinity for various metal ions, particularly copper. Its synthesis typically involves the reaction of iminodiacetic acid with 2-acetamidoethanol. ADA has been extensively studied for its potential applications in various fields, including:
- **Metal ion complexation and removal:** ADA's strong chelating ability makes it effective in sequestering metal ions from solutions, with applications in water treatment and metal recovery.
- **Biomedical applications:** ADA's copper complex has been investigated for its potential use in treating copper-related disorders, such as Wilson's disease.
- **Analytical chemistry:** ADA is used as a reagent in analytical chemistry for the determination of metal ions, forming stable complexes that can be quantified using various analytical techniques.
- **Catalysis:** ADA and its metal complexes can serve as catalysts in various organic reactions, promoting selective transformations.
ADA is a versatile compound with diverse applications stemming from its ability to bind metal ions. Ongoing research continues to explore its potential in various fields.'
N-(2-acetamido)iminodiacetic acid: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid : A tricarboxylic acid amide that is a Good's buffer substance, pKa = 6.6 at 20 degreeC. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 117765 |
| CHEBI ID | 43960 |
| SCHEMBL ID | 233033 |
| MeSH ID | M0073686 |
Synonyms (58)
| Synonym |
|---|
| STL355999 |
| (carbamoylmethyl-carboxymethyl-amino)-acetic acid |
| ADA , |
| n-(2-acetamido)iminodiacetic acid |
| ada, bioxtra, >=98% (titration) |
| ada, >=98% (titration) |
| carbamoylmethylaminodiacetic acid |
| 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid |
| 26239-55-4 |
| CHEBI:43960 |
| n-carbamoylmethyliminodi(acetic acid) |
| n-(2-amino-2-oxoethyl)-n-(carboxymethyl)glycine |
| DB02810 |
| n-(carbamoylmethyl)iminodiacetic acid |
| A0699 |
| BMSE000146 |
| glycine, n-(2-amino-2-oxoethyl)-n-(carboxymethyl)- |
| 2-[(2-amino-2-oxoethyl)-(carboxymethyl)amino]acetic acid |
| AKOS005267103 |
| unii-5c4r3o704e |
| 5c4r3o704e , |
| einecs 247-530-0 |
| 2,2'-((2-amino-2-oxoethyl)azanediyl)diacetic acid |
| c6h10n2o5 |
| 2-[(carbamoylmethyl)(carboxymethyl)amino]acetic acid |
| FT-0621892 |
| S6310 |
| BBL023210 |
| SCHEMBL233033 |
| ada [mi] |
| n-(carbamoylmethyl)iminodiacetatic acid |
| acetic acid, ((carbamoylmethyl)imino)di- |
| n-(2-acetamido)-iminodiacetic acid |
| DTXSID4067191 |
| W-107186 |
| n-[2-acetamido]iminodiacetic acid |
| QZTKDVCDBIDYMD-UHFFFAOYSA-N |
| n-(2-acetamido)imidodiacetic acid |
| iminodiacetic acid, n-(2-amino-2-oxoethyl)- |
| AKOS025395625 |
| mfcd00008031 |
| n-(2-acetamido)-2-iminodiacetic acid |
| AC-8316 |
| ada, bioultra, >=99.0% (t) |
| ada, vetec(tm) reagent grade, >=98% |
| a d a |
| acetic acid, 2,2'-[(2-amino-2-oxoethyl)imino]bis- |
| SY048625 |
| n-(carbamoylmethyl)-iminodiacetic acid |
| 2,2'-(2-amino-2-oxoethylazanediyl)diacetic acid |
| Q27093765 |
| AS-12375 |
| ada buffer |
| D70536 |
| CS-0015165 |
| HY-D0855 |
| EN300-1699288 |
| Z1143273443 |
Drug Classes (3)
| Class | Description |
|---|
| ADA | A nitrogen molecular entity with role as Good's buffer. |
| dicarboxylic acid | Any carboxylic acid containing two carboxy groups. |
| tricarboxylic acid amide | A carboxamide resulting from the formal condensation of one or more carboxy groups of a tricarboxylic acid with the amino group of any amino compound. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 21.93
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 21.93 (24.57) | | Research Supply Index | 2.08 (2.92) | | Research Growth Index | 4.71 (4.65) | | Search Engine Demand Index | 18.60 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |